SRPT
insider transactionsSarepta Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-20.4K
0 buy · 20.4K sell
Net value · 365d
-$417.4K
$0 in · $417.4K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 20.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Sell·S
Director
$123.2K
7.2K sh · $17.02
Own -80%
-
Sell·S
Chief Operating Officer
$294.2K
13.2K sh · $22.31
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 12, 2026 | Mayo Stephen | Sell S | 7.2K | $123.2K |
| Dec 16, 2025 | Estepan Ian Michael | Sell S | 13.2K | $294.2K |
Buy Sell Non-market (grant · exercise · gift)
About SRPT insider trading
This page tracks insider transactions for Sarepta Therapeutics, Inc. (SRPT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.